** Shares of drug developer Vera Therapeutics VERA.O rise 66.3% to $31.32 premarket
** VERA says its kidney disease drug, atacicept, met main goal in a late-stage study to treat IgA nephropathy
** IgA nephropathy causes a protein called immunoglobulin A to build up in the kidney
** Company says the drug reduced 46% protein in urine, stabilizing kidney function levels compared to placebo as measured on 24-hour kidney function test called urine protein creatinine ratio (UPCR)
** At week 36, atacicept, achieved statistically significant and clinically meaningful 42% reduction in UPCR test - VERA
** Company plans to submit a marketing application to the FDA in Q4 for the drug and expects for potential launch in 2026
** As of last close, VERA was down 55.2% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.